CA2490531C - Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity - Google Patents

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity Download PDF

Info

Publication number
CA2490531C
CA2490531C CA2490531A CA2490531A CA2490531C CA 2490531 C CA2490531 C CA 2490531C CA 2490531 A CA2490531 A CA 2490531A CA 2490531 A CA2490531 A CA 2490531A CA 2490531 C CA2490531 C CA 2490531C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2490531A
Other languages
English (en)
French (fr)
Other versions
CA2490531A1 (en
Inventor
Duane A. Burnett
Wen-Lian Wu
Thavalakulam K. Sasikumar
Martin S. Domalski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2490531A1 publication Critical patent/CA2490531A1/en
Application granted granted Critical
Publication of CA2490531C publication Critical patent/CA2490531C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2490531A 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity Expired - Fee Related CA2490531C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
US60/391,813 2002-06-27
PCT/US2003/020088 WO2004002987A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Publications (2)

Publication Number Publication Date
CA2490531A1 CA2490531A1 (en) 2004-01-08
CA2490531C true CA2490531C (en) 2011-03-22

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2490531A Expired - Fee Related CA2490531C (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Country Status (14)

Country Link
US (1) US7109207B2 (enExample)
EP (1) EP1532147B1 (enExample)
JP (1) JP4522853B2 (enExample)
CN (1) CN100374440C (enExample)
AR (1) AR040344A1 (enExample)
AT (1) ATE334983T1 (enExample)
AU (1) AU2003258957A1 (enExample)
CA (1) CA2490531C (enExample)
DE (1) DE60307289T2 (enExample)
ES (1) ES2266861T3 (enExample)
MX (1) MXPA05000185A (enExample)
PE (1) PE20040749A1 (enExample)
TW (1) TW200401777A (enExample)
WO (1) WO2004002987A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312056A (zh) * 2017-08-24 2017-11-03 广西师范学院 2‑(3’‑羟基‑17’‑孕甾烷基)‑5‑氟苯并咪唑的合成方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1867341A4 (en) * 2005-03-29 2009-07-29 Banyu Pharma Co Ltd THERAPEUTIC AGENT FOR NON-ALCOHOLIC FATBERS AND SCREENING METHODS FOR A DRUG-RELATED BIO-TREATMENT FOR THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATERS
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9090084B2 (en) 2010-05-21 2015-07-28 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312056A (zh) * 2017-08-24 2017-11-03 广西师范学院 2‑(3’‑羟基‑17’‑孕甾烷基)‑5‑氟苯并咪唑的合成方法
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Also Published As

Publication number Publication date
ES2266861T3 (es) 2007-03-01
PE20040749A1 (es) 2004-10-23
DE60307289D1 (de) 2006-09-14
JP2005535641A (ja) 2005-11-24
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
DE60307289T2 (de) 2007-10-18
CN1665812A (zh) 2005-09-07
CN100374440C (zh) 2008-03-12
EP1532147A1 (en) 2005-05-25
JP4522853B2 (ja) 2010-08-11
TW200401777A (en) 2004-02-01
HK1071567A1 (en) 2005-07-22
CA2490531A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
WO2004002987A1 (en) 2004-01-08
US20040024002A1 (en) 2004-02-05
EP1532147B1 (en) 2006-08-02
AU2003258957A1 (en) 2004-01-19
ATE334983T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
US6664273B2 (en) Piperidine based MCH antagonists for treatment of obesity and CNS disorders
EP1370528B1 (en) Mch antagonists and their use in the treatment of obesity
US7157472B2 (en) Neuropeptide Y Y5 receptor antagonists
EP1532147B1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
WO2005021528A1 (en) 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
EP1601664B1 (en) Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US7345042B2 (en) MCH antagonists for the treatment of obesity
EP1667679B1 (en) Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
AU2002244308A1 (en) MCH antagonists and their use in the treatment of obesity
HK1056877B (en) Mch antagonists and their use in the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130626